All In Biotech

Drug Trial Radar · NCT00986037

Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma

Last checked: Nov 19, 2026Latest source record: Nov 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

47

Planned (sponsor's estimate)

Start

Oct 2009

Primary completion

Jul 2010

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 29, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine the safety, tolerability and pharmacokinetics of ABT-308 in healthy volunteers and patients with mild to moderate controlled asthma.

Conditions

  • Asthma

Interventions

  • ABT-308Drug

    Single IV doses

  • ABT-308Drug

    Multiple SC doses x 3

  • PlaceboDrug

    Single IV dose

  • PlaceboDrug

    Multiple SC doses x 3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability will be determined by evaluation of adverse events, vital sign monitoring, physical examination, electrocardiograms, lung function and laboratory assessments.Time frame: 12 weeks after last dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.